翰森制药四款创新药续约纳入2024医保目录
财中社11月28日电翰森制药（03692）发布自愿公告，宣布旗下四款创新药续约纳入2024国家医疗保险目录。这四款药物包括甲磺酸阿美替尼片、甲磺酸氟马替尼片、伊奈利珠单抗注射液和聚乙二醇洛塞那肽注射液，将于2025年1月1日起正式执行。
甲磺酸阿美替尼片是中国首个原研三代表皮生长因子受体酪氨酸激酶抑制剂，适用于特定类型的非小细胞肺癌患者。甲磺酸氟马替尼片则用于治疗慢性髓性白血病。伊奈利珠单抗注射液针对视神经脊髓炎谱系疾病，而聚乙二醇洛塞那肽注射液是首个聚乙二醇修饰的GLP-1RA周制剂，适用于部分糖尿病患者。
此外，其他已纳入2023国家医保目录的创新药物如培莫沙肽注射液和艾米替诺福韦片，均在协议有效期内，有助于提高患者的可负担性和可及性。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10